Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Apolipoprotein A-1 (APOA1)

Mouse studies suggest APOA1 could help treat solid tumors. In mouse models for melanoma and lung cancer, expression of human APOA1 resulted in formation of smaller primary and metastatic tumors than no Apoa1 expression. In wild-type mice with murine or human melanomas, APOA1 decreased tumor burden and increased survival compared with vehicle. Next steps could include testing APOA1 in mouse xenograft models for other cancers.
Cerenis Therapeutics S.A.'s CER-522, a high-density lipoprotein mimetic based on a peptide analog of APOA1, is in Phase I testing to treat restenosis.

SciBX 6(24); doi:10.1038/scibx.2013.593
Published online June 20, 2013

Patented by the Cleveland Clinic; licensing status unavailable

Zamanian-Daryoush, M. et al. J. Biol. Chem.; published online
May 17, 2013;
doi:10.1074/jbc.M113.468967
Contact: Stanley L. Hazen, Cleveland Clinic, Cleveland, Ohio
e-mail:

hazens@ccf.org